Bristol-Myers Squibb

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
GoinPharma
Wed, 01/17/18 - 10:05 am
Eisai
Merck
Bristol-Myers Squibb
kidney cancer
Keytruda
Lenvima
Opdivo
Merck's Keytruda nabs new data to rival Bristol-Myers' Opdivo at fending off melanoma's return
Fierce Pharma
Mon, 01/15/18 - 10:37 am
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
melanoma
After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO
Fierce Pharma
Thu, 01/11/18 - 09:48 am
Bristol-Myers Squibb
Eliquis
Pharma CEOs
Giovanni Caforio
Pfizer
JPMHC 2018
2018 Healthcare And Biotech Outlook
Seeking Alpha
Sun, 01/7/18 - 12:41 pm
AbbVie
Abbott Labs
Amgen
Allergan
AstraZeneca
Gilead Sciences
Bristol-Myers Squibb
Bristol-Myers sees $3 billion tax hit in fourth quarter 2017
Yahoo/Reuters
Sat, 01/6/18 - 12:34 pm
Bristol-Myers Squibb
taxes
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
Fri, 01/5/18 - 10:28 am
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Top 10 stories that had pharma execs talking
Biopharma Dive
Thu, 01/4/18 - 12:02 pm
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Endpoints
Tue, 01/2/18 - 11:44 am
Bristol-Myers Squibb
AstraZeneca
Opdivo
Lynparza
China
Oncology business to keep leading pharma market in 2018
GoinPharma
Wed, 12/27/17 - 09:39 am
oncology
Merck
Bristol-Myers Squibb
Pfizer
Roche
3 Promising Cancer Immunotherapies to Watch in 2018
Yahoo/Motley Fool
Fri, 12/22/17 - 09:46 am
cancer
immuno-oncology
Incyte
epacadostat
Bristol-Myers Squibb
relatlimab
Nektar
NKTR-214
8 Takeout targets to watch in 2018
BioPharma Dive
Sat, 12/16/17 - 08:41 am
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
Endpoints
Thu, 12/14/17 - 11:16 am
Bristol-Myers Squibb
Opdivo
Ono Pharmaceutical
ONO-4578
immuno-oncology
drug development
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
Yahoo/Zacks.com
Sun, 12/3/17 - 11:21 am
Bristol-Myers Squibb
Opdivo
clinical trials
Docetaxel
China
Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Endpoints
Fri, 12/1/17 - 09:32 am
Bristol-Myers Squibb
Opdivo
China
Docetaxel
lung cancer
Innate shares crushed on second big setback for Bristol-Myers partnered lirilumab
Endpoints
Sat, 11/25/17 - 12:32 pm
Innate Pharma
Bristol-Myers Squibb
lirilumab
acute myeloid leukemia
How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas
Fierce Pharma
Thu, 11/16/17 - 11:27 am
drug launches
Keytruda
Harvoni
Opdivo
Merck
Bristol-Myers Squibb
Gilead Sciences
Forget BMS. Pfizer should chase a Biogen buy, analyst suggests
Fierce Pharma
Mon, 11/13/17 - 08:53 pm
Pfizer
Bristol-Myers Squibb
Biogen
M&A
Nektar Therapeutics (NKTR) Has Jumped To A New High On Study Results
NASDAQ.com
Mon, 11/13/17 - 10:54 am
Nektar
NKTR-214
Opdivdo
Bristol-Myers Squibb
Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
Endpoints
Fri, 11/10/17 - 11:35 am
Bristol-Myers Squibb
IDO1
BMS-986205
Incyte
bladder cancer
cervical cancer
The Only 3 Big Pharma Companies Growing Market Share
Motley Fool
Tue, 11/7/17 - 09:59 am
Bristol-Myers Squibb
Opdivo
Shire
Celgene

Pages